FMP
Histogen Inc.
HSTO
NASDAQ
Inactive Equity
Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.
0.02 USD
0 (0%)
HSTO Financial Statements
Year
2022
2021
2020
2019
CF from Operating Activities
-9.68M
-14.53M
-12.05M
-1.29M
Net Income
-10.64M
-15.01M
-18.82M
-3M
Depreciation & Amortization
140k
97k
98k
145k
Deferred Income Taxes
0
0
202k
-115k
Stock Based Compensation
502k
704k
618k
438k
Change in Working Capital
258k
126k
-1.3M
-508k
Accounts Receivable
66k
-21k
-34k
140k
Inventory
0
239k
-396k
678k
Accounts Payable
-1.01M
854k
-881k
493k
Other Working Capital
1.2M
-946k
12k
-1.82M
Other Non-Cash Items
61k
-450k
7.14M
1.75M
CF from Investing Activities
-216k
-241k
10.97M
-152k
Investments in Property, Plant & Equipment
-216k
-241k
-49k
-152k
Net Acquisitions
0
0
11.02M
0
Investment Purchases
0
0
0
0
Sales/Maturities of Investments
0
0
0
0
Other Investing Activites
0
-241k
10.97M
29.34M
CF from Financing Activities
3.32M
27.09M
5.78M
481k
Debt Repayment
-9k
-9k
-507k
-32k
Common Stock Issued
4.41M
20.74M
5.1M
513k
Common Stock Repurchased
0
0
0
0
Dividends Paid
0
0
0
0
Other Financing Activites
-585k
6.36M
226k
0
Free Cash Flow
-9.9M
-14.77M
-12.1M
-1.44M
Operating Cash Flow
-9.68M
-14.53M
-12.05M
-1.29M
Capital Expenditures
-216k
-241k
-49k
-152k
Cash at Beginning of Period
19.09M
6.77M
2.08M
3.04M
Cash at End of Period
12.51M
19.09M
6.77M
2.08M
Net Change In Cash
-6.58M
12.31M
4.7M
-962k
Retained Earning Schedule
Year
2022
2021
2020
2019
Retained Earnings (Previous Year)
-77.65M
-62.7M
-43.93M
-186.63M
Net Income
-10.62M
-14.4M
-25.77M
-4.9M
Stock Repurchases
0
0
0
0
Dividend Paid
0
0
0
0
Retained Earnings
-88.27M
-77.65M
-62.7M
-43.93M
Other Distributions
-10.62M
-14.95M
-18.77M
142.7M
PPE Schedule
Year
2022
2021
2020
2019
Gross PPE
5.09M
4.83M
4.68M
415k
Annual Depreciation
140k
97k
98k
145k
Capital Expenditure
-216k
-241k
-49k
-152k
Net PPE
5.17M
4.97M
4.63M
422k
Intangible and Goodwill Schedule
Year
2022
2021
2020
2019
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
